Profluent announces strategic partnership with Lilly to develop AI-designed recombinases for genetic medicine

• The collaboration combines Profluent’s groundbreaking AI platform with Lilly’s leading capabilities in genetic medicine

• AI-engineered recombinases aim to unlock kilobase-scale DNA editing capabilities for multiple diseases with serious unmet needs

EMERYVILLE, Calif., April 28, 2026–(BUSINESS WIRE)–Profluent, the pioneering AI company pioneering large-scale basic models for protein design, today announced a cross-program strategic research collaboration with Eli Lilly and Company (“Lilly”) to develop and commercialize tailored site-specific recombinases to treat diseases with serious unmet needs.

The collaboration is focused on enabling large-scale, precise DNA editing capabilities that remain unattainable with traditional gene editing systems. By combining Profluent’s groundbreaking AI models with Lilly’s clinical and genetic drug development capabilities, the companies aim to expand the scope and scalability of programmable gene editing therapeutics.

Many…